Specifically, quantitative IHC for Ki67 and progesterone receptor (PR) is recommended for classification of luminal (estrogen receptor (ER) positive) subtypes, while cytokeratin (CK) 5/6 and epidermal growth factor receptor (EGFR) are recommended to accurately identify basal-like breast cancers among tumors that are negative for all three standard clinical markers (ER, PR, and human epidermal growth factor receptor 2 (HER2)). Here, PGR is linked to breast cancer.